{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:47:49Z","timestamp":1760384869517,"version":"build-2065373602"},"reference-count":46,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T00:00:00Z","timestamp":1510531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to a lack of reference blood concentrations in the literature, the forensic evaluation of prothipendyl findings in blood samples is difficult. Interpretations with regard to the assessment of blood concentrations as well as an estimation of the ingested prothipendyl amounts were often vague. To describe a concentration range in clinical samples, prothipendyl and prothipendyl sulfoxide concentrations were determined in serum samples of 50 psychiatric patients receiving 40\u00a0mg, 80\u00a0mg, or 160\u00a0mg doses of prothipendyl. The analyses of prothipendyl and prothipendyl sulfoxide were carried out using validated methods of high performance liquid chromatography coupled to triple quadrupole mass spectrometry (LC\u2013QQQ\u2013MS), respectively. 40 mg doses caused average prothipendyl serum concentrations of 18.0\u00a0ng\/mL (1\u00a0hour after intake) and 7.9\u00a0ng\/mL (10.5\u00a0hours after intake), while 80\u00a0mg doses caused averages of 42.6\u00a0ng\/mL and 15.2\u00a0ng\/mL at the mentioned times of sampling. Irrespective of the given dose, prothipendyl concentrations below 30\u00a0ng\/mL were observed in 80% of the patient samples taken 1\u00a0hour after ingestion as well as in 90% of the samples collected 10.5\u00a0hours after administration. Serum concentrations of the Phase I metabolite prothipendyl sulfoxide averaged 4.3\u00a0ng\/mL (1\u00a0hour after intake) and 3.6\u00a0ng\/mL (10.5\u00a0hours after intake). Possible drug\u2010drug interactions regarding absorption and metabolism of prothipendyl are discussed. Results of the herein presented study are useful for the interpretation of analytical prothipendyl findings in forensic toxicology. The utility of the described concentration range is demonstrated by discussing two death cases involving prothipendyl findings.<\/jats:p>","DOI":"10.1002\/dta.2319","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:46:41Z","timestamp":1507855601000},"page":"1009-1016","source":"Crossref","is-referenced-by-count":6,"title":["Range of therapeutic prothipendyl and prothipendyl sulfoxide concentrations in clinical blood samples"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-9860","authenticated-orcid":false,"given":"Michael","family":"Kr\u00e4mer","sequence":"first","affiliation":[{"name":"Institute of Forensic Medicine, Department of Forensic Toxicology University Bonn  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Heese","sequence":"additional","affiliation":[{"name":"Department of Addiction Disorders and Psychotherapy LVR Hospital Bonn  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Banger","sequence":"additional","affiliation":[{"name":"Department of Addiction Disorders and Psychotherapy LVR Hospital Bonn  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Madea","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Department of Forensic Toxicology University Bonn  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Hess","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Department of Forensic Toxicology University Bonn  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,13]]},"reference":[{"issue":"49","key":"e_1_2_6_2_1","first-page":"19","article-title":"CYP450\u2010Wechselwirkungen: Interaktionen niederpotenter Neuroleptika","volume":"112","author":"Petri H","year":"2015","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"e_1_2_6_3_1","unstructured":"Teva Pharmaceutical Industries limited. Fachinformation (Zusammenfassung der Merkmale des Arzneimittels\/SPC). Dominal\u00ae.http%3A%2F%2Fwww.teva.de%2Findex.php%3FeID%3DdumpFile%26amp%3Bt%3Df%26amp%3Bf%3D37835%26amp%3Bg%3D-1%26amp%3Br%3D11068%252C11068%26amp%3Btoken%3D2b90148eb05f27cb473610efc2a68cfd0c84623c. Accessed September 1 2017."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.07.011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.01.001"},{"key":"e_1_2_6_6_1","first-page":"502","article-title":"Properties of a purified liver microsomal mixed function amine oxidase","author":"Ziegler DM","year":"1971","journal-title":"Flavins and Flavoproteins"},{"issue":"6","key":"e_1_2_6_7_1","first-page":"195","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011","volume":"21","author":"Hiemke C","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/15.1.35"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2006.05.021"},{"key":"e_1_2_6_10_1","unstructured":"SciFinder\u00ae.https:\/\/scifinder.cas.org\/scifinder\/view\/scifinder\/scifinderExplore.jsf. Accessed September 26 2017."},{"issue":"3","key":"e_1_2_6_11_1","first-page":"183","article-title":"Intraluminal pH of the human gastrointestinal tract","volume":"46","author":"Fallingborg J","year":"1999","journal-title":"Danish Med Bull."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.20.040180.001133"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejpb.2016.11.034","article-title":"Food, gastrointestinal pH, and models of oral drug absorption","volume":"112","author":"Abuhelwa AY","year":"2017","journal-title":"Eur J Pharm Biopharm: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1975.tb00568.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/55.12.1189"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127009803801105"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/48.12.1181"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1985.tb02262.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(70)90278-5"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02007.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0579-2"},{"issue":"3","key":"e_1_2_6_22_1","first-page":"307","article-title":"Cytochrome P450 polymorphism\u2013molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs","volume":"65","author":"Tomaszewski P","year":"2008","journal-title":"Acta Pol Pharm"},{"issue":"9","key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew BS","year":"2000","journal-title":"Drug Metab Dispos."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04251.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2002.tb00186.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.202556"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/js970316d"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2004.tb00028.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1993.tb00219.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.033878"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746040-00002"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.009043"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199713010-00005"},{"issue":"12","key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV\u20101 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P\u2010450","volume":"27","author":"Erickson DA","year":"1999","journal-title":"Drug Metab Dispos."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629090-00002"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.030551"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0740-5"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11317580-000000000-00000"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200004000-00012"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2010.01619.x"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2012.08.050"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11441"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb01813.x"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a289cb"},{"key":"e_1_2_6_45_1","unstructured":"Ratiopharm GmbH. Fachinformation. Olanzapin\u2010ratiopharm\u00ae Tabletten.http%3A%2F%2Fwww.ratiopharm.de%2Findex.php%3FeID%3DdumpFile%26amp%3Bt%3Df%26amp%3Bf%3D39347%26amp%3Bg%3D-1%26amp%3Br%3D1894%252C1894%26amp%3Btoken%3D9f0c38a390b0c301861283edf381f496d3c480b3. Accessed September 1 2017."},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.53.4.282"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0379-0738(01)00530-8"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:22:37Z","timestamp":1760383357000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,13]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/dta.2319"],"URL":"https:\/\/doi.org\/10.1002\/dta.2319","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"type":"print","value":"1942-7603"},{"type":"electronic","value":"1942-7611"}],"subject":[],"published":{"date-parts":[[2017,11,13]]}}}